Orphazyme Revenue and Competitors
Estimated Revenue & Valuation
- Orphazyme's estimated annual revenue is currently $13.2M per year.
- Orphazyme's estimated revenue per employee is $1,095,833
- Orphazyme's total funding is $263.3M.
- Orphazyme's current valuation is $79.8M. (January 2022)
Employee Data
- Orphazyme has 12 Employees.
- Orphazyme grew their employee count by -77% last year.
Orphazyme Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $7910M | 1885 | 33% | $204.3M | N/A |
#2 | $31.9M | 188 | 21% | N/A | N/A |
#3 | $3.4M | 839 | 22% | $85.7M | N/A |
#4 | $13.2M | 12 | -77% | $263.3M | N/A |
#5 | $16.1M | 86 | 5% | N/A | N/A |
#6 | $2.6M | 14 | 8% | N/A | N/A |
#7 | $35M | 13 | 160% | N/A | N/A |
#8 | $8.7M | 106 | 93% | N/A | N/A |
What Is Orphazyme?
Danish biotech company listed on Nasdaq Copenhagen (TICKER: ORPHA.CO), with a late-stage drug pipeline, developing new treatment options for orphan protein-misfolding diseases, including sporadic Inclusion Body Myositis (sIBM), Amyotrophic Lateral Sclerosis (ALS), Niemann Pick Type C (NPC), and Gaucher. Anticipated completion of three potential registration studies by end 2020, with the first potential marketing authorization in 2020.
keywords:N/A
$263.3M
Total Funding
12
Number of Employees
$13.2M
Revenue (est)
-77%
Employee Growth %
$79.8M
Valuation
N/A
Accelerator
Orphazyme News
Orphazyme is a late-stage biopharmaceutical company developing arimoclomol for Niemann-Pick disease type C (NPC). Orphazyme is headquartered in...
Copenhagen, Denmark, March 31, 2022 Orphazyme A/S in restructuring (ORPHA.CO) (Orphazyme or the Company), a late-stage...
Copenhagen, Denmark, March 29, 2022 Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (Orphazyme or the Company), a late-stage...
Orphazyme announced that it and Worldwide Clinical Trials will continue their collaboration through the long-term extension of a Phase 3 study ...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.9M | 12 | -25% | N/A |
#2 | $1.2M | 12 | 50% | N/A |
#3 | $1M | 12 | N/A | N/A |
#4 | $15M | 12 | N/A | N/A |
#5 | $1M | 12 | N/A | N/A |
Orphazyme Executives
| Name | Title |
|---|---|
| Christophe Bourdon | Chief Executive Officer |
| Thomas Jensen | Chief Scientific Officer |
| Thomas Blaettler | Chief Medical Officer |
| Birgitte Olander | CRO Oversight Specialist |
| Kim Stratton | Former CEO |
| Pernille Carlsen | Chief People Officer |
| Theresa Stevens | Chief Business Officer, Corporate Secretary |
| Patrick Lennon | VP, Analytics & Operations |
| Kevin McCann | Vice President, Head of Finance |
| Molly Painter | President - US |
| Izabella Tyszler | VP, Marketing & Sales |
| Bent Hygum | VP, Global Head of Quality |